Search results for "MESH: Registries*"

showing 9 items of 9 documents

Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic st…

2017

IF 7.702; International audience; The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were p…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyMale0301 basic medicinePediatricsMultivariate analysisMESH: RegistriesMESH : AgedMESH: ComorbidityComorbidityMESH : Lymphoma Large B-Cell DiffuseMESH: Aged 80 and over0302 clinical medicineInternational Prognostic IndexMESH : ChildMESH: ChildMESH : Population Surveillance[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleRegistriesYoung adultChildAged 80 and overMESH: AgedMESH: Middle AgedMESH : PrognosisRelative survivalMESH: Patient Outcome Assessment[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedMESH : AdultPrognosisMESH : Patient Outcome Assessment3. Good healthMESH: Young AdultPopulation SurveillanceMESH: Survival Analysis030220 oncology & carcinogenesisMESH : ComorbidityMarital statusFemaleFranceLymphoma Large B-Cell DiffuseNon-Hodgkin LeukemiaAdultmedicine.medical_specialtyAdolescentMESH : MaleMESH: Factor Analysis StatisticalMESH : Young AdultMESH : Factor Analysis StatisticalMESH: PrognosisMESH: Population SurveillanceMESH: Social ClassYoung Adult03 medical and health sciencesMESH : AdolescentInternal medicineMESH : Social ClassmedicineHumansMESH : Middle AgedMESH : Aged 80 and overMESH : FranceSurvival analysisAgedMESH: AdolescentMESH: Humansbusiness.industryMESH : HumansMESH: Adultmedicine.diseaseSurvival AnalysisComorbidityMESH: MalePatient Outcome AssessmentMESH: France030104 developmental biologySocial ClassMESH: Lymphoma Large B-Cell DiffuseMESH : Survival AnalysisFactor Analysis StatisticalbusinessMESH: FemaleDiffuse large B-cell lymphomaMESH : RegistriesHaematologica
researchProduct

Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients

2020

Background and Purpose— We aimed to determine the safety and mortality after mechanical thrombectomy in patients taking vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs). Methods— In a multicenter observational cohort study, we used multiple logistic regression analysis to evaluate associations of symptomatic intracranial hemorrhage (sICH) with VKA or DOAC prescription before thrombectomy as compared with no anticoagulation. The primary outcomes were the rate of sICH and all-cause mortality at 90 days, incorporating sensitivity analysis regarding confirmed therapeutic anticoagulation. Additionally, we performed a systematic review and meta-analysis of literature on this to…

MaleMESH: RegistriesAdministration Oral030204 cardiovascular system & hematology0302 clinical medicineInterquartile rangeMESH: ThrombectomyRegistriesStrokeThrombectomyMESH: AgedMESH: Middle AgedMESH: Follow-Up StudiesMiddle Aged3. Good healthddc:StrokeMESH: Administration OralFemale[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Cardiology and Cardiovascular MedicineMESH: Intracranial HemorrhagesCohort studymedicine.medical_specialty610 Medicine & healthMESH: AnticoagulantsLower riskMESH: Stroke03 medical and health sciencesMeta-Analysis as TopicInternal medicinemedicineHumansMESH: Meta-Analysis as TopicMedical prescriptionAgedAdvanced and Specialized NursingMESH: Humansbusiness.industryAnticoagulantsOdds ratiomedicine.diseaseFactor Xa inhibitorsMESH: MaleStroke treatmentIntracranial hemorrhagesObservational studyNeurology (clinical)MESH: Systematic Reviews as TopicbusinessMESH: Female030217 neurology & neurosurgeryFollow-Up StudiesSystematic Reviews as Topic
researchProduct

Characteristics and treatment regimens across ERS SHARP severe asthma registries

2020

Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many …

Severe asthmaPediatricsMESH: RegistriesMESH: AsthmaCross-sectional studyRespiratory SystemMedizin[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract0302 clinical medicineMESH: BelgiumBelgiumMedicine researchAnti-Asthmatic AgentsRegistries030212 general & internal medicine[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology10. No inequality11 Medical and Health SciencesNetherlands2. Zero hungereducation.field_of_studySHARP CRCMESH: Administration InhalationMESH: Anti-Asthmatic Agents3. Good healthEuropeItalyMESH: PolandMESH: Swedenmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyMESH: HungaryPopulationInvestigació mèdicaSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesMESH: Cross-Sectional StudiesAdministration InhalationMESH: SpainmedicineHumanseducationAsmaRetrospective StudiesAsthmaSwedenHungaryMESH: Humansbusiness.industrySettore MED/09 - MEDICINA INTERNAMESH: ItalyMESH: Retrospective StudiesRetrospective cohort studyOriginal Articlesasthmamedicine.diseaseAsthmaClinical trialCross-Sectional StudiesClinical research030228 respiratory systemSpainMESH: NetherlandsMESH: EuropePolandbusinessBody mass indexMepolizumabEuropean Respiratory Journal
researchProduct

Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)

2017

IF 3.398; International audience; The prognosis of patients with acute myocardial infarction (AMI) has notably improved in the past 20 years. Using the French Registry of ST-Elevation and Non-ST-elevation Myocardial Infarction (FAST-MI) 2010 registry, we investigated whether previous manifestations of atherosclerotic disease (i.e., previous MI, or a history of any form of atherosclerotic disease) are at truly increased risk compared with those in whom AMI is the first manifestation of the disease. FAST-MI 2010 is a nationwide French registry including 3,079 patients with AMI, among whom 1,062 patients had a history of cardiovascular atherosclerotic disease and 498 patients had a history of …

MaleMESH : Atherosclerosismedicine.medical_treatmentMESH : MortalityMyocardial InfarctionMESH : AgedMESH : Prospective StudiesAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDiseaseMESH : Cerebrovascular Disorders0302 clinical medicineMedicineLongitudinal StudiesProspective StudiesMESH: Coronary Artery DiseaseMyocardial infarctionCoronary Artery BypassMESH: Treatment OutcomeCause of deathAged 80 and overeducation.field_of_studyMESH: Middle AgedHazard ratioMESH : Platelet Aggregation InhibitorsPrognosisMESH: Case-Control Studies3. Good healthMESH: Myocardial InfarctionMESH: Angiotensin Receptor AntagonistsMESH : Angiotensin-Converting Enzyme InhibitorsCardiology and Cardiovascular MedicineMESH: Percutaneous Coronary InterventionMESH : Case-Control Studiesmedicine.medical_specialtyMESH : Angiotensin Receptor AntagonistsMESH: Prognosis03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedMESH : Coronary Artery DiseaseMESH : Aged 80 and overMESH: Hydroxymethylglutaryl-CoA Reductase InhibitorseducationMESH: Age DistributionAgedMESH: HumansMESH: MortalityProportional hazards modelMESH: Coronary Artery BypassMESH : HumansCase-control studyMESH : Proportional Hazards Modelsmedicine.diseaseMESH : Coronary Artery BypassCase-Control StudiesMESH: FemaleMESH: RegistriesMESH : Age Distribution030204 cardiovascular system & hematologyMESH: AtherosclerosisMESH: Proportional Hazards ModelsMESH: Cause of DeathMESH: Aged 80 and overMESH : Percutaneous Coronary InterventionRisk FactorsMESH: Risk FactorsCause of DeathMESH : FemaleRegistries030212 general & internal medicineMESH: Longitudinal StudiesMESH : Longitudinal StudiesMESH: AgedMESH : PrognosisMESH: Angiotensin-Converting Enzyme InhibitorsMESH: Adrenergic beta-AntagonistsMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsTreatment OutcomeMESH: Platelet Aggregation InhibitorsCardiologyFemaleMESH: Cerebrovascular DisordersFranceMESH : MaleAdrenergic beta-AntagonistsMESH : Adrenergic beta-AntagonistsPopulationMESH : Treatment OutcomeMESH: Multivariate AnalysisAngiotensin Receptor AntagonistsAge DistributionInternal medicineMortalityMESH : FranceProportional Hazards ModelsMESH : Cause of Deathbusiness.industryMESH : Hydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Multivariate AnalysisPercutaneous coronary interventionAtherosclerosisMESH: MaleMESH: Prospective StudiesMESH: FranceCerebrovascular DisordersMultivariate AnalysisHydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Myocardial InfarctionbusinessPlatelet Aggregation InhibitorsMESH : RegistriesThe American Journal of Cardiology
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Quality, comparability and methods of analysis of data on childhood cancer in Europe (1978-1997): report from the Automated Childhood Cancer Informat…

2006

International audience; In collaboration with 62 population-based cancer registries contributing to the Automated Childhood Cancer Information System (ACCIS), we built a database to study incidence and survival of children and adolescents with cancer in Europe. We describe the methods and evaluate the quality and internal comparability of the database, by geographical region, period of registration, type of registry and other characteristics. Data on 88,465 childhood and 15,369 adolescent tumours registered during 1978-1997 were available. Geographical differences in incidence are caused partly by differences in definition of eligible cases. The observed increase in incidence rates cannot b…

Cancer ResearchPediatricsDatabases FactualMESH: RegistriesMESH : Child Preschool[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineMESH : ChildNeoplasmsMESH: ChildEpidemiologyMedicineMESH: NeoplasmsRegistries030212 general & internal medicineMESH: IncidenceChildeducation.field_of_studyIncidenceIncidence (epidemiology)ComparabilityMESH: Infant NewbornQuality - methods - childhood cancer - EuropeMESH : InfantMESH : AdultMESH: InfantMESH : Incidence3. Good healthEuropeMESH: Reproducibility of ResultsOncologyChild Preschool030220 oncology & carcinogenesisMESH: Survival AnalysisAdultmedicine.medical_specialtyAdolescentPopulationMESH : EuropeMEDLINE[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Databases FactualMESH : Infant Newborn03 medical and health sciencesEnvironmental healthMESH : AdolescentHumanseducationSurvival analysisMESH: AdolescentMESH: Humansbusiness.industryMESH : Reproducibility of ResultsMESH: Child PreschoolMESH : HumansInfant NewbornInfantReproducibility of ResultsCancerMESH: Adultmedicine.diseaseSurvival AnalysisMESH: Databases FactualMESH : NeoplasmsData qualityMESH: EuropeMESH : Survival AnalysisbusinessMESH : Registries
researchProduct

Cardiac rehabilitation and 5-year mortality after acute coronary syndromes: The 2005 French FAST-MI study.

2016

IF 2.271; International audience; Background. - Clinical studies have shown a beneficial effect of cardiac rehabilitation (CR) on mortality.Objective. - To study the effect of CR prescription at discharge on 5-year mortality in patients with acute myocardial infarction (AMI).Methods. - Participants, from the 2005 French FAST-MI hospital registry, were 2894 survivors at discharge, divided according to AMI type: ST-segment elevation myocardial infarction (STEMI; n=1523) and non-STEMI (NSTEMI; n=1371). The effect of CR prescription on mortality was analysed using a Cox proportional hazards model.Results. - At discharge, 22.1% of patients had a CR prescription. Patients referred to CR were youn…

MaleMESH: Chi-Square Distributionmedicine.medical_treatmentMESH : Acute Coronary SyndromeMyocardial InfarctionMESH : AgedMESH : Prospective StudiesCardiac rehabilitationMESH: Risk Assessment0302 clinical medicineMyocardial infarctionProspective StudiesReferral and ConsultationMESH: Treatment OutcomeRehabilitationMESH: Middle AgedGeneral MedicineMESH: Follow-Up Studies3. Good healthMESH: Myocardial InfarctionMESH : Patient DischargeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute myocardial infarctionMortalitéRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedAcute Coronary SyndromeMESH: Kaplan-Meier EstimateAgedChi-Square DistributionMESH: HumansMESH : Chi-Square DistributionProportional hazards modelMESH: Patient DischargeMESH : HumansPatient survivalMESH : Follow-Up Studiesmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Acute Coronary SyndromeST-segment elevation myocardial infarctionMESH: FemaleTime FactorsMESH: RegistriesKaplan-Meier Estimate030204 cardiovascular system & hematologyMESH : Referral and ConsultationMESH: Proportional Hazards ModelsOlder patientsRisk FactorsMESH: Risk FactorsMESH : Female030212 general & internal medicineRegistriesMESH : Risk AssessmentMESH: AgedEjection fractionNon–ST-segment elevation myocardial infarctionMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsPatient DischargeTreatment OutcomeFemaleFranceMESH : Time FactorsMESH : MaleMESH : Treatment OutcomeMESH: Multivariate AnalysisMESH : Kaplan-Meier EstimateMESH: Referral and ConsultationInternal medicineInfarctus du myocarde sans sus-décalage du segment STmedicineIn patientcardiovascular diseasesMedical prescriptionMortalityRéadaptation cardiaqueMESH : FranceProportional Hazards Modelsbusiness.industryInfarctus du myocarde avec sus-décalage du segment STMESH: Time FactorsMESH : Multivariate AnalysisMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceInfarctus du myocarde aiguMultivariate AnalysisMESH : Myocardial InfarctionbusinessMESH : RegistriesFollow-Up Studies
researchProduct

Trends of incidence and survival in squamous-cell carcinoma of the anal canal in France: a population-based study.

2016

IF 2.415; International audience; Data on anal cancer epidemiology are rare. The aim of this study was to report on trends of incidence and survival for anal cancer in France before the implementation of the human papilloma virus vaccine. This analysis was carried out on 1150 squamous-cell carcinomas of the anal canal diagnosed from 1989 to 2004 in a population of 5.7 million people covered by eight population-based cancer registries. Time trends in incidence were modeled using an age-period-cohort model. Net survival rates were obtained using the recently validated unbiased Pohar-Perme estimator. The incidence of squamous-cell carcinoma of the anal canal increased from 0.2 to 0.5/100 000 p…

MaleEpidemiologyMESH : Aged[ SDV.CAN ] Life Sciences [q-bio]/CancerMESH: Anus NeoplasmsMESH: Research Papers: Gastrointestinal Cancer0302 clinical medicineMESH : ChildMESH: ChildMedicineMESH: IncidenceMESH : Carcinoma Squamous CellChildeducation.field_of_studyMESH: Middle AgedObstetricsMESH : InfantMESH: Carcinoma Squamous CellMESH: Follow-Up StudiesAnal canalAnus NeoplasmsPrognosisResearch PapersMESH: InfantMESH : Incidence3. Good healthSurvival RateOncologyMESH: Young AdultChild Preschool030220 oncology & carcinogenesisCarcinoma Squamous Cell030211 gastroenterology & hepatologymedicine.medical_specialtyMESH : Research Papers: Gastrointestinal CancerMitomycinMESH : Young AdultUnited-StatesMESH: Prognosis03 medical and health sciencesMESH : AdolescentHumansAnal cancerMESH : Middle AgedMESH : Anus NeoplasmseducationAgedGynecologyMESH: AdolescentMESH: HumansMESH : HumansMESH: Child PreschoolPublic Health Environmental and Occupational HealthInfantMESH : Follow-Up StudiesMESH: AdultEpidermoid Carcinomamedicine.diseaseCervical-cancerincidenceRandomized-trialMESH: FemaleCancer ResearchMESH: RegistriesMESH : Child PreschoolRisk FactorsMESH: Risk FactorsMESH : FemaleRegistriesCervical cancerMESH: AgedMESH : PrognosisIncidence (epidemiology)SmokingMESH: Infant NewbornMESH : AdultMiddle AgedMESH : Survival RateMESH : Risk Factorsmedicine.anatomical_structureFemaleFranceAdultHuman-PapillomavirusRiskAdolescentMESH: Survival Rateanal cancerMESH : MalePopulationHuman Papilloma Virus Vaccine[SDV.CAN]Life Sciences [q-bio]/CancerCancer IncidenceMESH : Infant NewbornsurvivalYoung Adultcancer registryMESH : FranceSurvival rateRadiotherapybusiness.industryInfant NewbornCancerMESH: MaleMESH: FrancebusinessMESH : RegistriesFollow-Up Studies
researchProduct